Pet Cancer Therapeutics Market Explore Future Growth 2018-2026 by Global Top Players – Aratana Therapeutics, AB Science, Karyopharm Therapeutics, Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB

Coherent Market Insights has announced the addition of the “Pet Cancer Therapeutics Market Size Status and Forecast 2026”, The report classifies the global Pet Cancer Therapeutics Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

This report studies the global Pet Cancer Therapeutics Speaker market, analyzes and researches the Pet Cancer Therapeutics Speaker development status and forecast in North America, Europe, Asia Pacific, Latin America and Rest of the World. This report focuses on the top players in global market, like Aratana Therapeutics, AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, VetDC, Karyopharm Therapeutics, Regeneus, Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis

Request a sample copy : https://www.coherentmarketinsights.com/insight/request-sample/1284

Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer. The ongoing research activities undertaken by the scientists for the development of novel formulations and therapies is expected to accelerate the market growth. For instance, the scientists at University of Veterinary Medicine are currently exploring the molecular basis of cancer progression in canine cell lines, stating that the modern cancer therapy can be revolutionized with the introduction of targeted therapies.

The pet cancer therapeutics include chemotherapy drugs, targeted therapies, combination therapies, and immunotherapy vaccines, which are commonly recommended by the veterinary doctors. The drugs are mostly recommended to treat various conditions such as lymphoma, mast cell tumors, fibrosarcoma, hemangiosarcoma, and others. Currently, a wide range of formulations are available in the global market for the treatment of pet cancers, which can be administered in the form of tablets, injections or can be applied topically. Thus, the large variety of treatment options has made it easy for the pets to receive effective cancer treatment suitable to curb the condition.

Market Growth

The major factor driving growth of the pet cancer therapeutics market include robust number of pipeline drugs for the treatment of highly prevalent conditions such as lymphoma and melanoma. For instance, in 2017, Aratana Therapeutics received approval from the United States Department of Agriculture (USDA) Center for Veterinary Biologics for canine osteosarcoma vaccine- AT-014 for the treatment of dogs diagnosed with osteosarcoma, one year of age or older. The drug candidate was licensed exclusively from Advaxis, Inc. and is currently in the pivotal trial. Moreover, the private and government organizations such as Veterinary Cancer Society, Petco Foundation, and Animal Cancer Foundation are working together to formulate novel drugs for dogs and cats, which is a major factor expected to propel growth of the pet cancer therapeutics market over the forecast period. However, lack of awareness regarding pet diseases, high cost, and adverse effects of the drugs are the factors restraining pet cancer therapeutics market growth.

Increasing number of research grants to launch various anti-cancer therapies for veterinary cancer treatment is expected to be a major factor driving growth of the global pet cancer therapeutics market in near future. For instance, in 2017, Animal Cancer Foundation (ACF) received a US$ 1 million grant from the Blue Buffalo Foundation to support comparative oncology research, which aimed to study similarities between naturally occurring cancers in people and pets and find effective treatment in both species. Also, in 2016, the Petco Foundation and Blue Buffalo Foundation invested US$ 2.35 million to support pet cancer research and treatment, as it represents a major cause of illness and premature death in affected species worldwide. Moreover, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to create a biobank of dog tumors for providing insights on cancer cure through research, in order to develop the most effective cancer therapy. Furthermore, organizations such as Animal Cancer Foundation, Petco Foundation, Veterinary Cancer Society, and PetCure Oncology are conducting oncology research such as canine cancer genome project to understand the genetic makeup of cancer tumors in animals, in order to discover targeted drug therapies with least toxic doses. However, increasing adoption of alternative treatment methods such as herbal medications, homeopathy and adverse effects such as diarrhea, musculoskeletal disorder, anorexia and high cost associated with pet cancer treatment are the factors restraining the market growth.

Global Pet Cancer Therapeutics Market, By Therapy Type:

Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy

Global Pet Cancer Therapeutics Market, By Pet Type:
Cat
Dog
Horse

Global Pet Cancer Therapeutics Market, By Mode of Administration:

Oral
Intravenous
Topical

Global Pet Cancer Therapeutics Market, By Application:

Lymphoma
Mast Cell Cancer
Melanoma
Mammary and Squamous Cell Cancer
Others

What Information does this report contain?

-Historical data coverage: 2013 to 2017; Growth Projections: 2018 to 2026.
-Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
-6-7 year performance forecasts: major segments covering applications, top products and geographies.
-Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Increasing prevalence of cancer indicates a need to adopt approved novel therapies, which are proved to be highly effective for the treatment of cancers in pets, thus, augmenting the pet cancer therapeutics market growth during the forecast period. According to the study by Fetch a Cure, 2015, dogs and cats have a higher incidence of tumors than humans, where dogs are 35 times more likely to develop skin cancer, 4 times more likely to develop breast tumors, and 8 times more likely to develop bone cancer. According to the study published by Animal Cancer Foundation, 2017, approximately around 25% of all dogs will develop a tumor at some point in their life. Furthermore, increasing number of relapsed cancer rates and the availability of relapsed/ refractory therapeutics integrated with veterinarian recommendation is expected to additionally generate the revenue for the market players.

Else place an Inquire before Purchase “Pet Cancer Therapeutics Market Size, Status and Forecast 2026: https://www.coherentmarketinsights.com/insight/talk-to-analyst/1284

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.